NASDAQ:GRTS - Gritstone bio Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $12.00
  • Forecasted Upside: 247.83 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.45
▲ +0.02 (0.58%)

This chart shows the closing price for GRTS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Gritstone bio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRTS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRTS

Analyst Price Target is $12.00
▲ +247.83% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Gritstone bio in the last 3 months. The average price target is $12.00, with a high forecast of $12.00 and a low forecast of $12.00. The average price target represents a 247.83% upside from the last price of $3.45.

This chart shows the closing price for GRTS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Gritstone bio. This rating has held steady since January 2022, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
2/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
5/16/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
8/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
11/12/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/10/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/10/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/9/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/9/2022HC WainwrightLower Price Target$15.00 ➝ $12.00High
3/14/2022HC WainwrightLower Price TargetBuy$24.00 ➝ $15.00High
9/20/2021HC WainwrightReiterated RatingBuy$24.00High
8/10/2021HC WainwrightReiterated RatingBuy$24.00Medium
1/21/2021BTIG ResearchBoost Price TargetBuy$17.00 ➝ $35.00Medium
1/20/2021HC WainwrightBoost Price TargetBuy$16.00 ➝ $24.00High
1/20/2021Robert W. BairdDowngradeOutperform ➝ Underperform$8.00High
8/6/2020HC WainwrightReiterated RatingBuy$16.00Low
7/14/2020BTIG ResearchLower Price TargetPositive ➝ Buy$31.00 ➝ $17.00Low
3/12/2020HC WainwrightReiterated RatingBuyHigh
1/15/2020CowenReiterated RatingBuyMedium
12/12/2019CowenReiterated RatingBuyLow
7/25/2019Robert W. BairdInitiated CoverageOutperform ➝ Outperform$17.00Medium
5/13/2019CowenReiterated RatingBuyHigh
4/1/2019HC WainwrightReiterated RatingBuy$17.00Medium
3/27/2019Berenberg BankInitiated CoverageBuyMedium
3/14/2019Raymond JamesInitiated CoverageOutperform ➝ Outperform$20.00High
3/7/2019HC WainwrightInitiated CoverageBuy ➝ Buy$17.00Low
12/11/2018BTIG ResearchBoost Price TargetBuy$31.00Low
10/23/2018CowenInitiated CoverageOutperformMedium
10/23/2018BarclaysInitiated CoverageOverweight$25.00Medium
10/23/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$18.00Medium
10/23/2018BTIG ResearchInitiated CoverageBuy ➝ Buy$26.00Medium
(Data available from 8/9/2017 forward)

News Sentiment Rating

0.42 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
1/11/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
2/10/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
3/12/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
4/11/2022
  • 0 very positive mentions
  • 5 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
5/11/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/10/2022
  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
8/9/2022

Current Sentiment

  • 4 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Gritstone bio logo
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Read More

Today's Range

Now: $3.45
Low: $3.38
High: $3.62

50 Day Range

MA: $2.53
Low: $1.98
High: $3.45

52 Week Range

Now: $3.45
Low: $1.71
High: $14.42

Volume

1,003,322 shs

Average Volume

568,674 shs

Market Capitalization

$251.19 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.51

Frequently Asked Questions

What sell-side analysts currently cover shares of Gritstone bio?

The following Wall Street analysts have issued research reports on Gritstone bio in the last twelve months: HC Wainwright.
View the latest analyst ratings for GRTS.

What is the current price target for Gritstone bio?

1 Wall Street analysts have set twelve-month price targets for Gritstone bio in the last year. Their average twelve-month price target is $12.00, suggesting a possible upside of 247.8%. HC Wainwright has the highest price target set, predicting GRTS will reach $12.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $12.00 for Gritstone bio in the next year.
View the latest price targets for GRTS.

What is the current consensus analyst rating for Gritstone bio?

Gritstone bio currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GRTS will outperform the market and that investors should add to their positions of Gritstone bio.
View the latest ratings for GRTS.

What other companies compete with Gritstone bio?

How do I contact Gritstone bio's investor relations team?

Gritstone bio's physical mailing address is 5858 HORTON STREET SUITE 210, EMERYVILLE CA, 94608. The company's listed phone number is (510) 871-6100 and its investor relations email address is [email protected] The official website for Gritstone bio is www.gritstoneoncology.com. Learn More about contacing Gritstone bio investor relations.